Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference

Rhea-AI Summary

Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) announced its participation in the Jefferies Virtual Global Healthcare Conference from June 2-4, 2020. Martin Driscoll, the President and CEO, will present on June 2, 2020, from 4:00 PM to 4:25 PM EDT. The presentation will be accessible on the company's website. Spring Bank focuses on developing novel therapeutics for viral infections, inflammatory diseases, and cancers, with its lead candidate SB 11285 aimed at treating selected cancers. For more details, visit www.springbankpharm.com.

HOPKINTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will be participating in the Jefferies Virtual Global Healthcare Conference, taking place June 2-4, 2020.

Martin Driscoll, Spring Bank’s President and CEO, will be providing a corporate presentation on June 2, 2020 from 4:00pm to 4:25pm EDT.

The corporate presentation will be accessible in the Investors & Media section of the company's website at https://ir.springbankpharm.com/. There are no planned webcasts for this event.

About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its STING product portfolio with its lead clinical product candidate, SB 11285, an intravenously-administered immunotherapeutic agent for the treatment of selected cancers, its STING antagonist compounds for the treatment of a broad range of inflammatory diseases and its STING agonist ADC program for potential oncology applications. For more information, please visit www.springbankpharm.com.

Investors:

LifeSci Advisors, LLC
Ashley R. Robinson
(617) 535-7742
Ashley@lifesciadvisors.com

Media:

McNeil, Gray & Rice
Kristin Nugent
Senior Account Supervisor
(617) 367-0100

Source: Spring Bank Pharmaceuticals, Inc.

FAQ

When is Spring Bank's presentation at the Jefferies Virtual Global Healthcare Conference?

Spring Bank's presentation is scheduled for June 2, 2020, from 4:00 PM to 4:25 PM EDT.

What is the focus of the presentation by Martin Driscoll?

Martin Driscoll will provide a corporate presentation discussing Spring Bank's developments and strategies in biopharmaceuticals.

What is the main product candidate of Spring Bank Pharmaceuticals?

The main product candidate of Spring Bank is SB 11285, which is being developed for the treatment of selected cancers.

Where can I access Spring Bank's corporate presentation?

The corporate presentation can be accessed in the Investors & Media section of Spring Bank's website.

What types of diseases does Spring Bank target?

Spring Bank develops therapeutics for viral infections, inflammatory diseases, and certain cancers.